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A B S T R A C T
Purpose
To further clarify the relationship between total cholesterol and cancer, which remains unclear.
Methods
We prospectively examined the association between total cholesterol and site-specific and
all-cancer incidence among 1,189,719 Korean adults enrolled in the National Health Insurance
Corporation who underwent a standardized biennial medical examination in 1992 to 1995 and
were observed for 14 years until cancer diagnosis or death.
Results
Over follow-up, 53,944 men and 24,475 women were diagnosed with a primary cancer. Compared
with levels less than 160 mg/dL, high total cholesterol ( 240 mg/dL) was positively associated
with prostate cancer (hazard ratio [HR], 1.24; 95% CI, 1.07 to 1.44; P trend  .001) and colon
cancer (HR, 1.12; 95% CI, 1.00 to 1.25; P trend  .05) in men and breast cancer in women (HR,
1.17; 95% CI, 1.03 to 1.33; P trend  .03). Higher total cholesterol was associated with a lower
incidence of liver cancer (men: HR, 0.42; 95% CI, 0.38 to 0.45; P trend  .001; women: HR, 0.32;
95% CI, 0.27 to 0.39; P trend  .001), stomach cancer (men: HR, 0.87; 95% CI, 0.82 to 0.93; P
trend  .001; women: HR, 0.86; 95% CI, 0.77 to 0.97; P trend  .06), and, in men, lung cancer
(HR, 0.89; 95% CI, 0.82 to 0.96; P trend  .001). Results for liver cancer were slightly attenuated
after additional adjustment for liver enzyme levels and hepatitis B surface antigen status (men: HR,
0.60; P trend  .001; women: HR, 0.46; P trend  .003) and exclusion of the first 10 years of
follow-up (men: HR, 0.59; P trend .001; women: HR, 0.44; P trend .001). Total cholesterol was
inversely associated with all-cancer incidence in both men (HR, 0.84; 95% CI, 0.81 to 0.86; P
trend .001) and women (HR, 0.91; 95% CI, 0.87 to 0.95; P trend .001), but these associations
were attenuated after excluding incident liver cancers (men: HR, 0.95; P trend  .001; women:
HR, 0.98; P trend  .32).
Conclusion
In this large prospective study, we found that total cholesterol was associated with the risk of
several different cancers, although these relationships differed markedly by cancer site.
J Clin Oncol 29:1592-1598. © 2011 by American Society of Clinical Oncology
INTRODUCTION
High total cholesterol is awell-established risk factor
for coronary heart disease and stroke.1,2 However,
the relationship between total cholesterol and the
risk of cancer remains uncertain. Cholesterol plays
an important role in cellular structure and function
and as a precursor to several biochemical pathways,
including the synthesis of vitamin D and steroid
hormones, thought to be involved in the etiology of
certain cancers.2-5 In some prospective studies, low
total cholesterol levels were associated with an in-
creased risk of cancer,6-11 spurring concern about
the potential health risks of cholesterol-lowering
drug use.12 These inverse associations were generally
restricted to thefirst fewyears of follow-up,6,8-11 possi-
bly as a result of a decline in cholesterol levels among
participants with prediagnostic cancer at baseline.13
Furthermore, prospective studies on the relationship
between total cholesterol and site-specific cancer risk
have been limited and somewhat contradictory. Some
of themore consistent findings include inverse associ-
ations with the risk of stomach10,14,15 and premeno-
pausal breast cancer16,17 andpositive associationswith
risk of high-grade, organ-confined or advanced pros-
tatecancer.10,18-20Fewprospectivestudieshavehadthe
power to examine total cholesterol in relation to less
commonly occurring cancers.
We examined the association between total
cholesterol and risk of all and site-specific cancer
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incidence in a prospective study of Korean men and women with
comprehensive data on health indicators and health behavior. With
approximately 1.2millionparticipants and79,000 incident cancers, to
our knowledge, this is the largest study of the relationship between
total cholesterol and cancer incidence to date.
METHODS
Study Population
Between 1992 and 1995, 1,329,525 Korean men and women aged 30 to
95 years participated in one biennial National Health Insurance Corporation
(NHIC) medical evaluation. Of the participants, 784,870 (59.0%) were en-
rolled in 1992; 367,903 (27.7%) were enrolled in 1993; 98,417 (7.4%) were
enrolled in 1994; and 78,335 (5.9%) were enrolled in 1995.
We excluded participants who died before January 1, 1993 (n  904);
who reported having cardiovascular disease, cancer, liver disease, or a respira-
tory disease at or before the initial visit (n  91,712); or who had missing
information on regular exercise, blood pressure, fasting blood glucose, body
mass index (BMI), or alcohol, or extremely low levels of BMI ( 16 kg/m2),
weight ( 30 kg), or height ( 1.30 m; n  44,557). We further excluded
participants withmissing or implausibly high or low total cholesterol levels
( 80 or  350 mg/dL; n  2,633). After applying these exclusions, the
final study population consisted of 1,189,719 participants (756,604 men
and 433,115 women).
Because the study used routinely collected data, consent was not specif-
ically obtained. The institutional review boards of Yonsei University and the
Johns Hopkins Bloomberg School of Public Health approved the study.
Data Collection
Enrollees in the KoreanNHIC undergo standardized biennial examina-
tions at local hospitals. During visits from1992 through 1995, information on
reproductive history,medical history, and lifestyle factors, including smoking,
alcohol consumption, and physical activity, was obtained through self-
administeredquestionnaires.Weightandheightmeasurementswere recorded
with participants wearing light clothing. Participants were seated for blood
pressure measurements. Fasting serum glucose and total cholesterol were
obtained during these visits for routine clinical purposes. Quality control
procedures were in accordance with the Korean Association of Laboratory
Quality Control.
Follow-Up and Outcome Classification
Follow-up of each participant began on the date in which fasting blood
samples were collected (1992 to 1995) and ended on the date of cancer diag-
nosis, death, loss to follow-up, or administrative censoring (December 31,
2006). Because reporting to the national cancer registry in Korea was only
approximately 90% complete during follow-up,21 claims data for the NHIC
generated from hospital admission files were used to identify additional first
admission events for cancer. In Korea, professionally trained and certified
medical chart recorders abstracted charts and assigned discharge diagnoses
and codes in a standardized fashion. Since 2003, this system has also become
the main data source for the Korean Central Cancer Registry.22 In this study,
participants with a primary cancer were identified by either a positive report
from the national cancer registry or by a hospital admission for a cancer diag-
nosis.
Statistical Analysis
Total cholesterol was categorized using cut points of less than 160,
160 to 179, 180 to 199, 200 to 239, and 240 mg/dL, in line with a recent
Table 1. Sex-Specific Distributions of Baseline Characteristics by Total Cholesterol in the Korean Cancer Prevention Study (1992 to 2006)
Characteristic
Total Cholesterol
 160 mg/dL 160-179 mg/dL 180-199 mg/dL 200-239 mg/dL  240 mg/dL
Mean SD Mean SD Mean SD Mean SD Mean SD
Men
No. 143,906 156,876 171,241 209,137 75,444
Age, years 44 12 44 11 45 11 46 11 47 10
Body mass index, kg/m2 22.5 2.5 22.9 2.5 23.2 2.5 23.6 2.5 24.1 2.5
Systolic blood pressure, mmHg 122.3 15.4 123.1 15.3 124.2 15.6 125.7 16.2 128.1 17.0
Fasting serum glucose, mg/dL 89.9 21.7 90.6 21.7 91.9 22.8 94.2 25.5 99.0 32.9
Smoking status, %
Never 21.3 21.1 21.0 20.3 19.4
Former 19.0 19.5 20.0 20.7 21.1
Current 59.7 59.4 59.1 59.1 59.5
High blood pressure, % 16.8 18.3 20.3 23.7 28.7
Any alcohol use, % 76.2 76.7 77.0 77.3 77.3
Physically active, % 27.4 28.0 28.8 29.4 29.7
Women
No. 77,808 85,800 92,675 123,567 53,265
Age, years 44 12 47 12 49 12 52 12 55 11
Body mass index, kg/m2 22.2 2.9 22.7 3.0 23.2 3.1 23.7 3.1 24.3 3.1
Systolic blood pressure, mmHg 116.6 16.6 118.8 17.7 121.1 18.7 123.9 19.8 127.5 21.1
Fasting serum glucose, mg/dL 86.2 17.5 87.6 18.7 89.4 20.6 92.0 24.8 97.0 32.8
Smoking status, %
Never 96.1 95.1 94.3 93.8 90.9
Former 1.3 1.7 1.9 2.5 3.1
Current 2.6 3.3 3.8 4.8 6.0
High blood pressure, % 11.7 15.1 19.1 24.2 31.0
Any alcohol use, % 13.8 14.4 14.4 14.5 14.6
Physically active, % 14.4 15.7 16.8 17.7 18.1
Abbreviation: SD, standard deviation.
Systolic blood pressure  140 mmHg or diastolic blood pressure  90 mmHg.
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prospective study of total cholesterol and cancer risk in Japanese men and
women.10 We considered total cholesterol levels between 200 and 240
mg/dL as borderline high and levels 240 mg/dL as high.
Cox proportional hazards models with attained age as the underlying
time metric, with late entry defined as the age in which participants enrolled
onto the cohort,wereused to calculate hazard ratios (HRs) and95%CIs for all
and site-specific cancer incidence according to total cholesterol level,modeled
both categorically and continuously (per 20 mg/dL). Trend tests for all and
site-specific cancers were conducted using the Wald test statistic for total
cholesterolmodeled as a continuous variable. Allmodelswere stratified by sex
and adjusted for cigarette smoking (never-smoker, former smoker, currently
smoking  20 cigarettes per day, or currently smoking  20 cigarettes per
day), alcohol consumption (0, 25, 25 to 49, 50 to 99, or 100 g/d), BMI
(calculated as weight in kilograms divided by height in meters squared),
physical activity (exercises v does not exercise), hypertension (systolic blood
pressure 140 mmHg or diastolic blood pressure 90 mmHg), and fasting
serum glucose (continuous). Because information on family history of cancer
and reproductive variables was only available for a subset of participants and
adjustment for these variables didnotmaterially change the results,wedidnot
include these covariates in thefinalmodels.Allmodelswere tested for andmet
the proportional hazards assumption.
In sensitivity analyses, liver cancer models were further adjusted for
hepatitis B surface antigen status and fasting ALT and AST levels, although
restricting the analysis to participants with this informationmeant that the
number of incident liver cancers was substantially reduced (by 2,881 in
men and 1,457 in women). We examined the results after excluding the
first 5 years of follow-up to investigate the potential influence of undiag-
nosed cancer on total cholesterol levels. Breast cancer models were strati-
fied by attained age (before v after age 50) to investigate potential
differences by menopausal status.
All analyses were conducted using SAS version 9.1 (SAS Institute, Cary,
NC). All statistical tests were two sided, and P .05 was considered statisti-
cally significant.
RESULTS
Themeanage at cohort entrywas 44.9 years formenand49.3 years for
women. Mean total cholesterol levels were 190.9 mg/dL in men and
194.1 mg/dL in women. Compared with participants with low total
cholesterol levels ( 160 mg/dL) at baseline, participants with high
levels ( 240 mg/dL) were typically older; had a higher BMI and
higher fasting serumglucose; andweremore likely to have high blood
pressure, to drink alcohol, and to exercise. Compared with men,
women were less likely to be current or former smokers, to consume
any alcohol, and to exercise (Table 1).
Of 756,604 men and 433,115 women included in the study,
53,945 men and 24,475 women were diagnosed with cancer during a
mean follow-up time of 12.7 years. Stomach (n 18,012), lung (n
10,866), and liver (n  10,161) cancers were the most commonly
diagnosed malignancies in this population (Appendix Table A1, on-
line only, lists age-specific incidence rates).
Relationship Between Cholesterol and Site-Specific
Cancer Incidence
Compared with low total cholesterol ( 160 mg/dL), high total
cholesterol ( 240mg/dL) was associated with a reduced risk of liver
cancer in men (HR, 0.42; 95% CI, 0.38 to 0.45; P trend .001) and
women (HR, 0.32; 95% CI, 0.27 to 0.39; P trend  .001; Tables 2
and 3). Additional adjustment for liver enzymes (ALT and AST) and
hepatitis B surface antigen status slightly attenuated these associations
(men: HR, 0.60; 95% CI, 0.54 to 0.67; P trend .001; women: HR,
0.46; 95% CI, 0.24 to 0.87; P trend  .003). A significant inverse
dose-response association between total cholesterol and risk of stom-
ach cancer was observed in men (HR, 0.87; 95% CI, 0.82 to 0.93; P
trend .001),whereas a borderline significant trendwas observed for
stomach cancer in women (HR, 0.86; 95%CI, 0.77 to 0.97; P trend
.06). Total cholesterol was also significantly inversely associated with
lung cancer in men (HR, 0.89; 95% CI, 0.82 to 0.96; P trend .001)
but not in women. Although a significant inverse trend association
was observed for esophageal cancer inmen (P trend .01), the risk
in the highest compared with lowest cholesterol group was not





 160 mg/dL 160-179 mg/dL 180-199 mg/dL 200-239 mg/dL  240 mg/dL
No. HR† No. HR† 95% CI No. HR† 95% CI No. HR† 95% CI No. HR† 95% CI
Esophagus 299 1.0 284 0.85 0.73 to 1.00 318 0.84 0.71 to 0.98 340 0.69 0.59 to 0.80 173 0.92 0.76 to 1.11 .01
Stomach 2,578 1.0 2,770 0.93 0.88 to 0.98 3,111 0.90 0.85 to 0.94 4,054 0.89 0.85 to 0.94 1,536 0.87 0.82 to 0.93  .001
Colon 687 1.0 864 1.06 0.96 to 1.17 1,023 1.06 0.96 to 1.17 1,418 1.10 1.00 to 1.20 569 1.12 1.00 to 1.25 .05
Rectum 627 1.0 775 1.05 0.95 to 1.17 900 1.04 0.94 to 1.15 1,169 1.01 0.92 to 1.12 478 1.06 0.94 to 1.19 .75
Liver 2,193 1.0 1,790 0.69 0.65 to 0.74 1,879 0.62 0.58 to 0.66 1,944 0.48 0.45 to 0.51 670 0.42 0.38 to 0.45  .001
Pancreas 331 1.0 342 0.88 0.76 to 1.03 385 0.84 0.73 to 0.97 528 0.86 0.75 to 0.99 213 0.88 0.74 to 1.05 .17
Lung 1,683 1.0 1,740 0.92 0.86 to 0.98 1,907 0.88 0.82 to 0.94 2,444 0.87 0.81 to 0.92 956 0.89 0.82 to 0.96  .001
Prostate 366 1.0 456 1.06 0.93 to 1.22 562 1.10 0.97 to 1.26 777 1.14 1.01 to 1.29 329 1.24 1.07 to 1.44 .001
Kidney 211 1.0 221 0.87 0.72 to 1.05 309 1.03 0.86 to 1.22 427 1.05 0.89 to 1.24 170 1.04 0.85 to 1.28 .29
Gallbladder 176 1.0 183 0.89 0.73 to 1.10 201 0.84 0.68 to 1.03 268 0.84 0.69 to 1.02 115 0.91 0.71 to 1.15 .27
Bladder 315 1.0 378 1.03 0.89 to 1.20 449 1.05 0.91 to 1.21 671 1.18 1.03 to 1.35 245 1.10 0.93 to 1.30 .10
All cancer 10,249 1.0 10,641 0.89 0.87 to 0.92 11,946 0.86 0.84 to 0.88 15,166 0.83 0.81 to 0.85 5,943 0.84 0.81 to 0.86  .001
All cancer minus
liver cancer 8,056 1.0 8,851 0.94 0.92 to 0.97 10,067 0.92 0.90 to 0.95 13,222 0.92 0.89 to 0.94 5,273 0.95 0.91 to 0.98  .001
Abbreviation: HR, hazard ratio.
Calculated by including total cholesterol as a continuous variable in the multivariable models.
†Models used attained age as the underlying time metric and were adjusted for cigarette smoking, alcohol drinking, body mass index, fasting serum glucose,
hypertension, and physical activity.
Kitahara et al
1594 © 2011 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
significantly reduced (HR, 0.92; 95% CI, 0.76 to 1.11), and no
association was observed in women.
High ( 240mg/dL) versus low ( 160mg/dL) total cholesterol
waspositively associatedwith riskofprostate cancer inmen(HR,1.24;
95% CI, 1.07 to 1.44; P trend  .001; Table 2) and breast cancer in
women (HR, 1.17; 95% CI, 1.03 to 1.33; P trend  .03; Table 3).
Althoughwe lacked data onmenopausal status for all of thewomen, a
sensitivity analysis of breast cancer incidence stratified by follow-up
time showed a similar association between total cholesterol ( 240 v
 160mg/dL) and breast cancer before age 50 years (HR, 1.17; 95%CI,
0.94 to 1.46) versus after age 50 years (HR, 1.14; 95%CI, 0.96 to 1.35; P
interaction .07). We observed a borderline significant positive dose-
response association for colon cancer inmen (HR, 1.12; 95%CI, 1.00 to
1.25;P trend .05; Table 2).
After excluding the first 5 years of follow-up, most of the
results, including the association for prostate cancer (2,168 men;
HR, 1.23; 95% CI, 1.05 to 1.45; P trend .002) and colon cancer
(3,836men; HR, 1.12; 95%CI, 0.99 to 1.27; P trend .05) in men,
were not substantially different. There were some slight differ-
ences, however. For instance, the association for breast cancer risk
was slightly stronger (2,748women;HR, 1.21; 95%CI, 1.04 to 1.41;
P trend .003), and the association for colon cancer inwomenwas
stronger and statistically significant (1,478 women; HR, 1.28; 95%
CI, 1.06 to 1.56; P trend .004). The inverse associations for liver
cancer risk remained even after exclusion of the first 10 years of
follow-up (men: n  2,658; HR, 0.59; 95% CI, 0.51 to 0.68; P
trend .001; women: n 407; HR, 0.44; 95% CI, 0.31 to 0.64; P
trend .001).
The site-specificHRsper 20mg/dLdifference in total cholesterol
for men and women are shown in Figs 1A and 1B, respectively. The
relationship of total cholesterol with site-specific cancer incidence
varied greatly, with approximately half of the HRs falling below unity
(ie, cancers of the liver, lung, stomach, gallbladder, pancreas, and, in
men, esophagus) and half falling above unity (ie, cancers of the rec-
tum, kidney, colon, bladder, prostate, breast, cervix, and, in women,
esophagus). However, with the exception of liver cancer, these risks
were fairly modest, with HRs between 0.95 and 1.05 per 20mg/dL.
Relationship Between Cholesterol and
All-Cancer Incidence
After adjusting for smoking, alcohol consumption, BMI, fasting
glucose, hypertension, and physical activity, all-cancer incidence de-
creased with increasing total cholesterol in bothmen ( 240 v 160
mg/dL; HR, 0.84; 95% CI, 0.81 to 0.86; P trend .001; Table 2) and
women (HR, 0.91; 95% CI, 0.87 to 0.95; P trend  .001; Table 3).
Excluding the first 5 years did not change the association with all-
cancer incidence considerably (men: n 40,056; HR, 0.87; 95% CI,
0.84 to 0.91; P trend .001; women: n 17,146; HR, 0.94; 95% CI,
0.89 to 1.00; P trend .007). In women, there was no association for
total cholesterolwith all-cancer incidence after excluding liver cancers
from the analysis; in men, the association was attenuated but re-
mained statistically significant (HR, 0.95; 95% CI, 0.91 to 0.98; P
trend .001; Tables 2 and 3).
To assess the internal validity of our study, we examined the
association of total cholesterol ( 240 v 160mg/dL)with the risk
of ischemic heart disease. TheHRwas 1.90 inmen (95%CI, 1.81 to
1.99; P trend .001) and 1.38 in women (95% CI, 1.28 to 1.48; P
trend .001).
DISCUSSION
Data from this large prospective study in Korea suggest that total
cholesterol levels have differing associations with cancer, depending






 160 mg/dL 160-179 mg/dL 180-199 mg/dL 200-239 mg/dL  240 mg/dL
No. HR† No. HR† 95% CI No. HR† 95% CI No. HR† 95% CI No. HR† 95% CI
Esophagus 11 1.0 12 0.82 0.36 to 1.87 22 1.24 0.60 to 2.57 25 0.91 0.44 to 1.87 14 1.06 0.47 to 2.37 .91
Stomach 575 1.0 656 0.89 0.80 to 1.00 897 1.01 0.91 to 1.12 1,265 0.93 0.84 to 1.03 570 0.86 0.77 to 0.97 .06
Colon 240 1.0 312 1.00 0.84 to 1.18 384 1.00 0.85 to 1.18 629 1.07 0.92 to 1.24 328 1.14 0.96 to 1.35 .06
Rectum 203 1.0 288 1.09 0.91 to 1.30 335 1.03 0.87 to 1.23 497 0.99 0.84 to 1.17 278 1.13 0.94 to 1.36 .60
Liver 399 1.0 342 0.63 0.54 to 0.72 348 0.50 0.44 to 0.58 410 0.37 0.32 to 0.42 186 0.32 0.27 to 0.39  .001
Pancreas 100 1.0 121 0.87 0.67 to 1.14 164 0.93 0.72 to 1.19 247 0.85 0.67 to 1.08 144 0.96 0.74 to 1.24 .83
Lung 293 1.0 354 0.91 0.78 to 1.06 439 0.92 0.79 to 1.07 711 0.95 0.83 to 1.09 339 0.91 0.78 to 1.07 .62
Kidney 37 1.0 64 1.37 0.91 to 2.05 66 1.18 0.79 to 1.77 114 1.35 0.93 to 1.97 52 1.28 0.83 to 1.98 .48
Gallbladder 68 1.0 86 0.93 0.68 to 1.28 130 1.12 0.83 to 1.50 180 0.96 0.72 to 1.27 86 0.89 0.64 to 1.23 .26
Bladder 31 1.0 45 1.10 0.70 to 1.74 72 1.44 0.94 to 2.19 91 1.15 0.76 to 1.75 57 1.45 0.92 to 2.27 .22
Breast 701 1.0 802 1.08 0.98 to 1.20 854 1.12 1.01 to 1.24 1,035 1.11 1.01 to 1.23 413 1.17 1.03 to 1.33 .03
Cervix 406 1.0 443 0.99 0.87 to 1.13 521 1.08 0.95 to 1.24 616 0.97 0.85 to 1.10 268 0.99 0.84 to 1.16 .67




cancer 3,553 1.0 4,188 0.98 0.94 to 1.03 5,001 1.02 0.98 to 1.07 6,874 0.98 0.94 to 1.02 3,174 0.98 0.94 to 1.03 .32
Abbreviation: HR, hazard ratio.
Calculated by including total cholesterol as a continuous variable in the multivariable models.
†Models used attained age as the underlying time metric and were adjusted for cigarette smoking, alcohol drinking, body mass index, fasting serum glucose,
hypertension, and physical activity.
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on cancer site. Total cholesterol levels were positively associated with
breast cancer in women and prostate and colon cancer in men. Con-
versely, total cholesterol was inversely associated with liver and stom-
achcancer inbothmenandwomenand lungcancer inmen.Although
we observed an inverse dose-response association for total cholesterol
with all-cancer incidence, these results seemed to be drivenmainly by
the strong inverse association with liver cancer. The potential influ-
ence of prediagnostic cancer on total cholesterol levelsmay have been
a source of bias in the current study,13 because the exclusion of inci-
dent cancer cases occurring in early follow-up strengthened the posi-
tive associations of colon and breast cancer in women and slightly
attenuated the association with liver cancer.
Undiagnosed liver disease could inhibit cholesterol metabo-
lism,23,24 possibly exaggerating the negative associationwith liver can-
cer incidence. However, further adjustment for serum ALT and AST
levels, two markers of liver inflammation and liver cell damage, and
hepatitis B surface antigen status slightly attenuated the results, sug-
gesting that undiagnosed liver cancer may only partially explain this
association. Two other prospective studies have examined the associ-
ation between total cholesterol and liver cancer incidence.10,11 Our
results are consistentwith thefindings froma smaller cohort of 33,000
Japanese men and women, in which an inverse association with liver
cancer was observed in both men and women, even after adjustment
for risk factors such as hepatitisC infection, alcohol intake, and smok-
ing; exclusion of the first 3 years of follow-up; and restriction of the
analysis topatientswithnonadvanced cancer.10 In contrast, an inverse
trend association between total cholesterol and liver cancer risk ob-
served in a cohort of Finnish male smokers was attenuated after
excluding thefirst 9 years of follow-up.11 The lowcholesterol compar-
ison group ( 203.9 mg/dL)11 included relatively high cholesterol
levels comparedwith that of both the Japanese study (160mg/dL)10
and our study; therefore, a possible increased risk of liver cancer at
lower total cholesterol levels may not have been observable in the
Finnish cohort.
Nine prospective studies have examined the relationship be-
tween total cholesterol and prostate cancer incidence.6,7,10,11,18-20,25,26
Apart from the current study, only one other prospective study
showedapositive associationbetween total cholesterol and total pros-
tate cancer incidence.10 Given the small number of incident prostate
cancers, most prospective studies were unlikely to have sufficient
power to detect modest relative risks (ie,  1.5). However, some
prospective studies have suggested that high total cholesterol may
increase the risk of high-grade or advanced, rather than total, prostate
cancer,18-20 and cholesterol-lowering drugs have been associatedwith
a reduced risk of advanced prostate cancers in observational studies.27
Althoughwe lacked information on cancer stage and grade, wemight
expect a higher proportion of advanced prostate cancers during
follow-up relative to most Western populations because prostate-
specific antigen screening was relatively uncommon in South Korea
during this time.
We also observed modest positive associations for total choles-
terol with risk of colon cancer in men and breast cancer in women.
Evidence from prospective studies generally does not support an as-
sociation between cholesterol and risk of colorectal cancer7,10,11,25,28
or breast cancer,10,25,29-33 except possibly an inverse association with
premenopausal breast cancer.16,17 Although the exact mechanisms
whereby high total cholesterol levels could lead to an increased risk of
cancer are unclear, cholesterol is involved in numerous biochemical
pathways that are potentially relevant in cancer initiation and/or pro-
gression, including vitamin D and steroid hormone synthesis.3-5 In
addition, compared with their normal counterparts, cancer cells have
higher levels of cholesterol-rich lipid rafts in the plasma membrane,
whichmaybe important in the transduction of several signaling path-
ways, including those relevant to cancer cell survival, such as Akt.34
Considering that our data were originally collected for routine
clinical purposes, it is plausible that confounding as a result of certain
unmeasured factorswas a source of bias in this study.Our resultswere
not substantially changedafter adjusting for several cancer risk factors,
Hazard Ratio (95% CI)
Hazard Ratio (95% CI)
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Fig 1. Hazard ratios and 95% CIs for total cholesterol (per 20 mg/dL) in relation
to site-specific cancer incidence in (A) Korean men and (B) Korean women in the
Korean Cancer Prevention Study (1992 to 2006). Models used attained age as the
underlying time metric and were adjusted for cigarette smoking, alcohol drinking,
body mass index, fasting serum glucose, hypertension, and physical activity.
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including BMI, alcohol consumption, cigarette smoking, physical ac-
tivity, and fasting serum glucose.35 Although we cannot rule out po-
tential confounding by diet in this study, previous studies found no
difference in the associations between total cholesterol and cancer
after further adjustment for total vegetable,10 total fat,7,15 saturated
and polyunsaturated fat,11 fiber,7,15 and vitamin15 intakes. We also
cannot rule out potential confounding by socioeconomic status be-
cause data on socioeconomic indicators, such as education, income,
or place of residence, were not ascertained. Total cholesterolmay also
be related to other cancer risk factors that were not measured in this
study, such as hepatitis C virus infection, although the prevalence of
anti–hepatitis C virus is only approximately 1% among adults in
SouthKorea.36 Another limitation of this study is the lack of informa-
tion on participants’ use of cholesterol-lowering drugs, which may
influence the development of cancer through a variety ofmechanisms
independent of cholesterol lowering, including the inhibition of
tumor growth, induction of apoptosis, inhibition of angiogenesis,
increases in mitotic abnormalities, and immunosuppression.37
However, evidence from randomized trials, although limited, does
not suggest a strong link between cholesterol-lowering drug use and
cancer incidence.37,38 We estimate that the prevalence of cholesterol-
lowering drug use would have been low (between 1% and 2%) in this
Korean population. We also lacked data on lipoprotein subfractions
and cancer subtypes (ie, estrogen receptor/progesterone receptor-
positive v -negative breast cancer, advanced v nonadvanced prostate
cancer, and proximal v distal colon cancer). Finally, total cholesterol
was measured from baseline blood draws only; thus, intraindividual
variation in cholesterol over timemay have attenuated our results.
Because the study included only government employees, teach-
ers, and their dependents, the study population was generally older
and includedahigherproportionofmenandmiddle-class individuals
compared with the general population of South Korea. Although the
incidence rates of cancer may differ for these reasons, we have little
reason to suspect that the associationswould differ between our study
and the general population.
Our studydoeshave several important strengths.The large sizeof
our study and the wide range of total cholesterol values provided
sufficient power to detect relatively modest effects, in contrast with
many previous studies. Comprehensive information on potential
confounding factors, suchas alcohol consumption, cigarette smoking,
BMI, physical activity, fasting serumglucose, bloodpressure, hepatitis
B surface antigen status,ALT, andAST,was collected.Withmore than
14 years of follow-up, we were able to assess the potential bias caused
by preclinical disease by excluding a considerable amount of early
follow-up time (up to 10 years).
This large prospective study of Korean adults provides novel
evidence that high cholesterol, or factors correlated with it, may be
positively associated with the risk of several malignancies, including
cancers of the prostate, breast, and colon. Although the relative risks
were modest, these effects, if causal, may translate into a reasonable
number of incident cancers in populations where high cholesterol
levels are more prevalent, such as the United States.39 The strong
inverse associationbetween cholesterol and liver cancer incidencewas
consistentwithprevious studies and seemed tobepartly, but not fully,
explained by undiagnosed liver disease.
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